



## Genenta has been Awarded to be the **First Prize** at China-Italy Best Start Up Showcase & Entrepreneurship Competition 2018/2019 (BSSEC)

October 14, 2019

ROME (Italy) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), today announced that won the first prize at the BSSEC, China-Italy Best Start Up Showcase and Entrepreneurship Competition 2018/2019. The Chinese venture capital firms, Esco Ventures and Guoqian Venture Capital Investment (Suzhou) were part of the jury that chose between 16 different start-ups in the life science sector. Stefania Mazzoleni, PhD represented Genenta at the competition. Stefania serves at Genenta as Project Manager.

### About Genenta Science

Genenta ([www.genenta.com](http://www.genenta.com)) develops an ex-vivo gene transfer strategy into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Genenta's proprietary product is Temferon™.

The targeted expression of the immunomodulatory molecule in TEMs is achieved combining a transcriptional and post-transcriptional microRNA-mediated control. Thanks to these mechanisms, TEMs become capable to express the immunomodulatory molecule (Interferon-alpha, "IFN-α") in the tumor microenvironment.

TEMs are endowed with a pro-angiogenic activity and are spontaneously and actively recruited by developing tumors to sustain their growth. Thanks to the immune-gene transfer, TEMs become the tool for the local delivery of the immunomodulatory molecule. In the preclinical models, the local IFN-α release triggered both a direct (anti-angiogenic, pro-apoptotic) and an indirect anti-tumor effect (immune response).

In contrast to antigen-restricted Chimeric Antigen Receptor T cells (CAR-T), Temferon™ may reach not only hematologic disorders but more importantly, also solid tumors. In addition, its immune-modulatory functions may trigger a long-lasting immune response towards multiple tumor antigens.

As a result, Temferon™ should be able to break the tumor immune-tolerance by reprogramming the tumor immune microenvironment.

Genenta obtained the regulatory approvals for two Phase I/II clinical trials in early relapse Multiple Myeloma patients after front line therapy and newly diagnosed Glioblastoma Multiforme patients.

Genenta's headquarter is in Milano (Italy) and Genenta has an office in Alexandria Center's LaunchLabs, New York (NY, USA). The Company is part of Assobiotech, Italia StartUp, and ELITE (London Stock Exchange Group).

Co-founders: Pierluigi Paracchi, Ospedale San Raffaele (OSR), prof. Luigi Naldini (Director SR-TIGET, San Raffaele Telethon Institute for Gene Therapy), and Bernhard Gentner (Hematologist and Physician-Scientist at OSR and SR-TIGET). Carlo Russo, MD serves as CMO.

Genenta raised more than €30M in three different rounds of financing.

Genenta Media/Investor Contact:

Valentina Brambilla, PhD

+39 388 789.15.41

[valentina.brambilla@genenta.com](mailto:valentina.brambilla@genenta.com)

GENENTA SCIENCE Srl

Ospedale San Raffaele - DiBit 1 - Via Olgettina, 58 - 20132 Milano (Italy)

LaunchLabs - Alexandria Center, 14th Floor - 430 East 29th Street - New York, NY 10016 (USA)